ValenzaBio
is a Maryland-based biopharmaceutical company that develops monoclonal antibody therapeutics for the treatment of autoimmune and inflammatory diseases... Read moreValenzaBio
is a Maryland-based biopharmaceutical company that develops monoclonal antibody therapeutics for the treatment of autoimmune and inflammatory diseases... Read more
Chairman & CEO
Patrick J. Crutcher
News
Jan 06, 2023
ExploreBit
ValenzaBio: ACELYRIN acquires ValenzaBio
Nov 03, 2022
Business Wire
Press Release: ValenzaBio : ValenzaBio Announces Positive Preliminary Data from Phase 1b/2a Trial of VB119, an Anti-CD19 Monoclonal Antibody for the Treatment of Primary Membranous Nephropathy
Jun 14, 2022
Contract Pharma
ValenzaBio: ProBioGen & ValenzaBio Enter Second Service Agreement
Mar 31, 2022
FirstWord Pharma
ValenzaBio: ValenzaBio Announces FDA Clearance of Investigational New Drug Application for VB421, an Anti-IGF-1R Monoclonal Antibody for the Treatment of Thyroid Eye Disease
Feb 15, 2022
BioSpace
ValenzaBio: ValenzaBio and Novelty Nobility Announce Exclusive License Agreement for Potential Best-in-Class Anti-c-KIT Monoclonal Antibody
Aug 09, 2021
Biospectrum Asia
ValenzaBio: ValenzaBio partners ProBioGen to maximize cell line productivity in Europe
Jul 28, 2021
Contract Pharma
ValenzaBio: ValenzaBio, ProBioGen Enter Cell Line Pact
Jul 28, 2021
Manufacturing Chemist
ValenzaBio: ValenzaBio licences ProBioGen s GlymaxX technology
Jun 23, 2021
BioPharma-Reporter
ValenzaBio: Lonza to provide manufacturing for ValenzaBio from China facility
Jun 21, 2021
Contract Pharma
ValenzaBio: Lonza and ValenzaBio Enter Clinical Manufacturing Agreement
